Document is current

Article History

Received: 30 April 2021

Accepted: 22 July 2021

First Online: 15 September 2021

Declarations

:

: WCG Institutional Review Board approval of the study protocol was obtained prior to study conduct and included a waiver of informed consent.

: Not applicable

: SR is an employee of F. Hoffmann-La Roche AG and is a member of the editorial board for BMC Medicine. TL and CS are employees of PHMR Ltd. JR is an employee of F. Hoffmann-La Roche AG. SW is an employee of Roche Products Ltd. VS reports other research funding/grant support for clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center, and Vegenics Pty Ltd.; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte Corporation, Novartis, and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Incyte Corporation, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, and R-Pharm US; and other relationship with Medscape.